JAK2 and COVID-19: Gain-of-function mutations like JAK2 V617 F result in constitutive activation of the pathway and may exacerbate hyperinflammatory responses, thereby worsening COVID-19 pathology (Elbadry et al. 2022; Pelkey et al. 2022).